Maxime Vallée PhD defense

On December 13th, Maxime Vallée, MD, successfully defended his thesis at the Faculté de Médecine et de Pharmacie at the Université de Poitiers. His research focused on tissular distribution of new beta-lactam antibiotics in renal and prostatic tissues in animal models.

Congratulations to him completing this important step in his academic and professional career!

 

 

We are hiring!

See all our job offers on our dedicated page.

 

International AMR Symposium

We are participating in the upcoming International AMR Symposium, hosted by the Institut Pasteur:
« Tackling Antibacterial and Antifungal Infections From Disease to Innovative Therapies »

📅 Dates: December 9–10, 2024
📍 Location: Paris, France

This event brings together global leaders to discuss groundbreaking approaches in the fight against antimicrobial resistance (AMR).

 

We are eager to share insights from 3 of our different projects:

📑 Poster Presentation for Anissa Benkhaled : « Apramycin-Gallium combination for the treatment of Acinetobacter baumannii pulmonary infections. »

📑Poster Presentation for Albane Rozenholc : « Dual AmpC and AmpD mutations in Pseudomoans aerugionsa : Unraveling the mechanisms of Resistance to Ceftazidime and avibactam. »

🎤 📑Short talk and Poster Presentation for Farras Daffia Imtiyaz : « Enhancing colistin efficacy against Multi-drug resistant Gram negative bacteria using Farnesol Loaded Lipid nanoparticles. »

💡 For more details, check out the symposium page.

Looking forward to connecting with many of you at this impactful event! Let’s work together to advance health and well-being.

 

 

The laboratory is once again partner in a JPIAMR project: COMBAT-AMR!

Antimicrobial combinations are an essential therapeutic strategy to combat antimicrobial resistance (AMR) and treat complex infections. So far, combinations have generally been derived empirically using sub-optimal drug choices and dosing ratios, including beta-lactam/beta-lactamase inhibitor combination treatments. Defining the optimal drug combination of antibiotics and the associated dosing schedules to maximise efficacy and minimise the risk for AMR selection is complex and requires extensive preclinical development.To advance development and optimization of combination treatments, and exploit their currently underused potential, there is an urgent need for alignment and integration of the assays to evaluate combination therapy novel suitable experimental and computational methodologies.

This project aims to develop a standardised toolbox of connected experimental and computational approaches tailored to the pre-clinical design of antibiotic combination treatments, which addresses current hurdles in the design and evaluation of antibacterial combinations, which are optimized towards treatment of AMR-associated pathogens and preventing AMR emergence. The tools and workflows will be applied to exemplar combinations to further evaluate their potential, and to demonstrate the application of the developed toolbox. The results will be used to seek regulatory qualification for the developed workflows and to guide the development of combination clinical breakpoints.

27th national congress of the French Society of Cytometry in Marseille, France

We will attend the 27th national congress of the French Society of cytometry in Marseille, France, scheduled from 17th to 19th December 2024.

Come and meet us, at the poster presentation delivered by Jonathan CLARHAUT.

« Development of a flow cytometry method to study antifungal tolerance in yeasts of medical interest »